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The use of induced pluripotent stem cells (iPSCs) has been postulated to be the most effective strategy for 
developing patient-specific respiratory epithelial cells, which may be valuable for lung-related cell therapy 
and lung tissue engineering. We generated a relatively homogeneous population of alveolar epithelial type II 
(AETII) and type I (AETI) cells from human iPSCs that had phenotypic properties similar to those of mature 
human AETII and AETI cells. We used these cells to explore whether lung tissue can be regenerated in vitro. 
Consistent with an AETII phenotype, we found that up to 97% of cells were positive for surfactant protein C, 
95% for mucin-1, 93% for surfactant protein B, and 89% for the epithelial marker CD54. Additionally, expos-
ing induced AETII to a Wnt/β-catenin inhibitor (IWR-1) changed the iPSC-AETII–like phenotype to a pre-
dominantly AETI-like phenotype. We found that of induced AET1 cells, more than 90% were positive for type I 
markers, T1α, and caveolin-1. Acellular lung matrices were prepared from whole rat or human adult lungs 
treated with decellularization reagents, followed by seeding these matrices with alveolar cells derived from 
human iPSCs. Under appropriate culture conditions, these progenitor cells adhered to and proliferated within 
the 3D lung tissue scaffold and displayed markers of differentiated pulmonary epithelium.
Introduction
Lung disease is the third-leading cause of death in the United 
States, with more than 400,000 deaths annually (1, 2). While lung 
transplantation is a possible treatment for people who have end-
stage lung disease, it is limited by the low availability of donor 
lungs; moreover, surgical, medical, and immunological complica-
tions cause considerable morbidity and mortality in this popula-
tion. As a result, many patients die each year while on a waiting list 
or because of transplant complications (1, 3, 4).
Transplantation of adult lung stem and progenitor cells or alve-
olar cells, isolated from human lung, is emerging as an alterna-
tive to whole-organ transplantation (5). However, this approach 
is also limited by the scarcity of human epithelial cells and the 
difficulties of expanding these cells in vitro. Moreover, the suc-
cessful engraftment of such cells in vivo in injured lungs has not 
yet been demonstrated (5–7).
One potential future treatment for severe lung disease is trans-
plantation with engineered lungs that are capable of gas exchange. 
To avoid immunological rejection, such engineered lungs should 
be created using individual-specific (autologous) lung and airway 
cells (3, 8, 9). Therefore, a substantial emphasis is being placed on 
identifying a reliable source of functional lung epithelial cells to 
be used in lung-related therapies (2, 10).
Induced pluripotent stem cells (iPSCs) are the product of adult 
somatic cell reprogramming to an embryonic-like state by induc-
ing a “forced” expression of specific pluripotent genes (11, 12). It 
is postulated that the use of human iPSCs may be the most effec-
tive strategy for developing respiratory epithelial cells that may 
be valuable in lung-related cell therapies and tissue engineering 
(13–15). Given that iPSCs can be derived from the patient to be 
treated, they could provide a cell source that is genetically identi-
cal to the patient, allowing tissue generated from these cells to 
avoid immune rejection (9, 12).
The differentiation of human ES cells (ESCs) and iPSCs into 
pulmonary epithelium has been challenging. Several research 
groups have reported the successful differentiation toward a 
range of pulmonary epithelial cell types, including both alveolar 
type II cells (AETII cells) and other airway epithelium, using a 
variety of protocols (1, 5, 14–19). However, conditions for direct-
ing hESCs or iPSCs to differentiate along an alveolar epithelial 
lineage with high homogeneity have not yet been reported, and 
most protocols generate a mixed population of epithelial cells 
from hESCs or iPSCs.
Recently, the focus in organ engineering has centered on decel-
lularizing complex organs such as heart, liver, and kidney, and 
using the acellular matrices as scaffolds for repopulation with 
organ-specific cells. Because the decellularized organ has the ECM 
template, it contains appropriate 3D architecture and regionally 
specific sites for cellular adhesion (3, 8). With ECM derived from 
donor lungs, the capacity to regenerate lung tissue from autolo-
gous cells (e.g., autologous iPSC-derived epithelium) would there-
fore constitute a major medical advance. One way to accomplish 
this in lung engineering is to differentiate human iPSCs (iPSCs) 
into respiratory epithelial cells and/or into putative postnatal 
stem cells of the respiratory system and to reseed the lung acel-
lular matrix with these cells (9).
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during the first 6 days of differentiation. iPSC were initially cul-
tured without serum for 48 hours with 100 ng/ml activin A, and 
then changed to a low-serum concentration provided with 1×B27 
culture medium. During the time that iPSCs were exposed to 
activin A, the majority of the cells in the colonies converted to 
DE cells, while those cells that did not gradually died, as moni-
tored through visual observation. After 6 days of differentiation, 
both iPSC clones (denoted as C1 and C2) stained positively for 
SOX17 and FOXA2, and the majority of the cells were positive for 
both SOX17 and FOXA2 (Figure 1C, Supplemental Figure 1, A–J, 
for C1 cells, and Supplemental Figure 2, A–J for C2 cells; supple-
mental material available online with this article; doi:10.1172/
JCI68793DS1). When we monitored endoderm marker expres-
sion using quantitative RT-PCR (qRT-PCR) for SOX17, CXCR4, 
and FOXA2, no expression of these markers was observed at day 0; 
In the present study, we report an efficient and consistent, step-
wise differentiation method to generate definitive endoderm (DE), 
anterior foregut endoderm (AFE), and subsequently, a relatively 
homogeneous population of human AETII and AETI cells from 
iPSCs (Figure 1A). These cells not only demonstrate the phenotype 
of mature hAETI and hAETII cells, but also express a high per-
centage of type I and II cell markers when compared with freshly 
isolated hAETI and hAETII cells. Additionally, these iPSC-derived 
AETII cells are capable of repopulating an acellular lung matrix 
and give rise to cell types that reside in the distal lung (Table 1).
Results
Efficient derivation of DE cells. Embryonic lung arises from DE (14, 
20, 21). Therefore, in the first step, we differentiated iPSC from 
DE by exposing them to saturating concentrations of activin A 
Figure 1
Schematic summarizing the experiment. (A) Schematic protocol for directed differentiation of iPSCs to AETII in vitro in 22 days. Cytokines were 
added at different steps indicated on top of panel. (B) Schematic summarizing the iPSC differentiation and decellularization-recellularization of 
both rat and human lung with iPSC-derived AETII cells. decell, decellularized. (C) Phase-contrast images of iPSCs at day 0, DE cells at day 6, 
and differentiated cells at day 15 and 22, which are termed AETII cells. Scale bars: 63 μm.
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followed by a decrease with time in culture (Supplemental Fig-
ure 6A for C1 cells, and Supplemental Figure 6B for C2). These 
results are expected, given that endoderm is a transient stage in 
lung development and is expected to peak and then fade as stem 
cells differentiate toward later phenotypes (22).
Prior to lung differentiation, all cells that will belong to the 
pulmonary lineage must first progress through a primordial pro-
genitor stage defined by the upregulation of the ventral marker 
NKX2.1 (1, 16). NKX2.1 (homeodomain-containing transcription 
factor) is the earliest known marker associated with commitment 
to thyroid and lung, but several studies suggest that NKX2.1 induc-
tion is indicative of commitment to a lung, rather than a thyroid 
fate (1, 14, 16). Replacing activin A with NOGGIN/SB-431542 
from day 6 to day 8, followed by the addition of a cocktail contain-
ing BMP4/Wnt3a/bFGF/KGF, induced NKX2.1 expression in the 
AFE cell population at day 13. Most of the NKX2.1-positive cells 
in both iPSC clones costained with the endoderm marker FOXA2 
(Figure 2, M and N, for C1 cells, and Supplemental Figure 3, M 
and N for C2). Additionally, flow cytometric analysis showed that 
24% ± 2% of the AFE cell population derived from C1 and 26% ± 3% 
from C2 was positive for NKX2.1, as compared with less than 1% 
in activin A–induced cells and in cells cultured in medium without 
NOGGIN/SB-431542 at day 13. Continuous activin A treatment 
from day 6 to day 8 without the addition of NOGGIN/SB-431542 
resulted in rare FOXA2+SOX2+ cells and few NKX2.1+ cells (Figure 
2O for C1 cells, and Supplemental Figure 3O for C2). Collectively, 
these expression data show that in activin A–induced DE, exposure 
to NOGGIN/SB-431542 results in a highly enriched population of 
cells with an AFE phenotype.
ECM protein effects on differentiation. In traditional stem cell 
cultivation/differentiation experiments, growth factors (GFs) 
are added in soluble form in order to provide signals for tissue-
specific differentiation (14, 15, 17, 18, 20). However, differen-
tiation has recently become increasingly linked to mechanobio-
logical concepts such as interaction between cells and the ECM 
(23–25). Moreover, during development, ECM protein expression 
represents some of the most important inducers of organ fate. 
Accordingly, before switching medium to NOGGIN/SB-431542 
to generate AFE from human pluripotent cells, the DE cells were 
split with trypsin and reseeded at a ratio of 1:1–2 on ECM-coated 
plates in medium containing NOGGIN/SB-431542 for 48 hours. 
We tested adhesion of DE cells to fibronectin, collagen I, collagen 
IV, Matrigel, and a mixture of human ECM proteins (consisting 
of collagens, laminin, fibronectin, tenascin, elastin, and a num-
ber of proteoglycans and glycosaminoglycans; Sigma-Aldrich). 
Fibronectin, collagen I, collagen IV, and laminin are principal 
components of lung matrix, and DE cells attach well to all of 
these proteins. However, mixed human ECM protein resulted in 
faster DE cell attachment and significantly higher expression of 
SPC, SPB, and NKX2.1 genes on both day 15 and day 30 (Supple-
mental Figure 4, A–C).
Efficient derivation of purified lung AETII from AFE. After differen-
tiation to AFE on day 8, the medium was switched to alveolar dif-
ferentiation medium containing FGF-10, EGF, WNT3a, KGF, and 
RA for 14 days on human ECM protein. These factors or reagents 
were chosen through empiric studies and are thought to play a 
crucial role in alveolar pneumocyte differentiation and lung devel-
opment (1, 14, 15, 17, 18, 20). Compared with other reports, we 
found that the differentiation cocktail that lacked BMP4 in the 
final stage resulted in distal markers, especially those associated 
expression then increased from day 0 to day 6 in iPSCs exposed to 
activin A (Supplemental Figure 1L, Supplemental Figure 6A for 
C1 cells, Supplemental Figure 2L, and Supplemental Figure 6B for 
C2). Flow cytometric analysis demonstrated that the cell popula-
tion derived from iPSCs at day 6 expressed a high percentage of 
markers associated with DE, including 92.71% ± 4.0% for CXCR4, 
83.76% ± 2.0% for SOX17, and 87.66% ± 1.2% for FOXA2 in C1; and 
87.23% ± 2.0% for CXCR4, 91.42% ± 3.0% for SOX17, and 83.54% 
± 1.8% for FOXA2 in C2 (Supplemental Figure 1M for C1 cells, 
and Supplemental Figure 2M for C2). We found our protocol was 
highly efficient for generating a relatively homogeneous popula-
tion of DE from iPSCs; based on the dual expression of SOX17 
and FOXA2 in iPSC clones, more than 85% of C1 and 89% of C2 
comprised endodermal cells (Supplemental Figure 1K for C1 cells 
and Supplemental Figure 2K for C2). Both the C1 clone (which is 
of fetal lung origin) and the C2 clone (which is derived from neo-
natal fibroblasts) yielded similar results. This suggests that this 
protocol may be generalized to other iPSC lines from other cell 
origins or that are reprogrammed using other techniques.
Generating AFE from DE cells. Following developmental para-
digms, directed differentiation of iPSCs to alveolar epithelium 
should proceed by generation of DE, followed by patterning into 
AFE. Differentiation of AFE cells from DE was induced by expos-
ing cells to NOGGIN (200 ng/ml) and SB-431524 (10 mM) for 2 
days per the conditions described previously by Green and col-
leagues (1, 14, 15). Application of NOGGIN/SB-431542 to DE 
yielded a highly enriched population of cells with strong expres-
sion of markers associated with the AFE phenotype, including 
SOX2, PAX9, and TBX1 in both clones. The majority of cells coex-
pressed SOX2 and FOXA2, as demonstrated by immunostaining 
at day 8 (Figure 2, A–J for C1 cells, and Supplemental Figure 3, 
A–J for C2). Cells that were negative for DE markers gradually 
died off after switching to AFE differentiation medium, as visu-
alized by microscopy. In addition, our results show that inhi-
bition of TGF-β signaling and activin A/nodal signaling with 
NOGGIN/SB-431542 was sufficient in the 2 iPSC clones tested 
to increase the anterior endoderm cell population (as defined 
by FOXA2+SOX2+) up to 92%–95% as compared with less than 
0.1% without NOGGIN/SB-431542 (Figure 2K for C1 cells, and 
Supplemental Figure 3K for C2). qRT-PCR revealed a relatively 
modest increase in both PAX9 and TBX1 when compared with 
expression of SOX2, which was highly expressed in AFE cells 
derived from both iPSC colonies at day 8 (Figure 2L for C1 cells, 
and Supplemental Figure 3L for C2). After activin A removal at 
day 6 and switching to NOGGIN/SB-431542, we observed that 
both CXCR4 and SOX17 decreased from day 6 to day 12. In the 
case of FOXA2, we observed an increase in expression at day 8, 
Table 1
Summary of lung development steps and corresponding  
markers at each step
Lung differentiation stages Markers
iPSC OCT4, SOX2, SSEA4, TRA1-60
DE CXCR4, SOX17, FOXA2
AFE NKX2.1, PAX9, TBX1, SOX2
AETII SPC, SPB, SPA, ICAM-1, NKX2.1
AETI T1α, caveolin-1, AQ5
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tron microscopy in the iPSC-derived AETII cells. TEM identifica-
tion of lamellar bodies is used as a method for positively identify-
ing type 2 pneumocytes. The TEM data clearly show the presence 
of lamellar bodies in the iPSC-derived AETII cells (Figure 3, A–F 
for C1 cells, and Supplemental Figure 5, A–F for C2). qRT-PCR 
demonstrated a high percentage of expression of type II cell mark-
ers in iPSC-AETII cells that was comparable to expression levels 
of freshly isolated human primary ATII cells (hATII cells) (Figure 
with type II pneumocytes. After day 22, the cells — now termed 
AETII cells (Figure 1, A and B) — were maintained in SAGM cul-
ture medium containing 1% FBS. AETII cells derived from both 
the C1 and C2 clones were strongly positive for type II markers, 
including pro-SPC, pro–surfactant protein B (pro-SPB), mucin-1, 
and surfactant protein A (SPA). In addition to the positive marker 
expression associated with type II cells, we also assayed for the 
presence of lamellar bodies, typical of human type II cells, by elec-
Figure 2
Characterization of cells at day 8 of differentiation to produce AFE. (A–I) Immunofluorescence analysis of AFE markers. (A, D, and G) DAPI 
staining for nuclei; (B, E, and H) PAX9-, TBX1- and SOX2-positive cells. (C, F, and I) Merge at day 8. (J) Immunofluorescence staining showing 
AFE cells are positive for both SOX2 and FOXA2. (K) Flow cytometric analysis of double-positive cells for SOX2 and FOXA2 in AFE cells at day 
8 compared with cells cultured in activin A and RPMI medium only (y axis: percentage of positive cells for FOXA2/SOX2 ). (L) mRNA expression 
of SOX2, TBX1 and PAX9 in AFE generated from DE cells in vitro at day 8 (data expressed as quantification of mRNA normalized to GAPDH and 
average fold change in gene expression over iPSCs; y axis, fold changes in gene expression compared with iPSC). (M) Expression of NKX2.1 on 
day 13 after induction AFE quantified by DAPI staining for nuclei, NKX2.1 positive cells, and merge. (N) Immunofluorescence staining showing 
NKX2.1 cells in AFE stained positive for FOXA2, indicating these cells are more lung progenitor rather than thyroid progenitor. (O) Flow cytometric 
analysis of positive cells for NKX2.1. Up to 24% of AFE cells were positive for NKX2.1 at day 13. (y axis, percentages of cells positive for NKX2.1). 
Bars indicate mean ± SEM of n = 3 independent experiments for qRT-PCR and flow cytometry. *P < 0.05. Scale bars: 31 μm.
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and Supplemental Figure 8, A–D for C2 cells). Between days 8 
and 22, NKX2.1+ cells proliferated slowly, ultimately leading to 
an increase in the number of NKX2.1- and SPC-positive cells. The 
amount of cell death, following the switch in culture medium to 
alveolar epithelium differentiation medium, was negligible when 
compared to the earlier medium switch from DE to AFE differen-
tiation medium from day 0 to day 8. Immunostaining for NKX2.1+ 
cells at different days (day 13, 18, and 21) demonstrated that colo-
nies expressing NKX2.1 were gradually expanded and overgrew the 
NKX2.1 negative cells. This ultimately led to an increase in the 
number of NKX2.1-positive cells, as shown by a gradual progres-
sion from 24% at day 13 to 94% at days 20–22.
Since several recent studies have reported CD166 and α6β4 to 
be markers of lung epithelial progenitors (26–29), we character-
ized the expression of these markers during the differentiation 
of iPSC to epithelial cells at several time points. Flow cytometry 
revealed that the percentage of CD166-positive cells gradually 
increased from 15% ± 0.8% at day 13 to 35% ± 1.4% at days 20–22 
during differentiation in the C1 clone. The expression of CD166 
subsequently decreased in mature cultures of iPSC-derived epi-
thelial cells at day 28. In the case of α6β4, the expression pro-
gressively increased from 10% ± 0.7% at day 13 to 25% ± 1.2% 
at day 18 in C1. By day 22 only 7%–8% of the cells were positive 
for α6β4. The same pattern of CD166 and α6β4 expression was 
observed in the C2 clone during differentiation from day 8 to 
day 22 (Supplemental Figure 9, A and B for C1 cells, and Supple-
mental Figure 9, C and D for C2 cells).
Replacing the NOGGIN/SB-431542 medium with differentia-
tion medium at day 9 of culture resulted in decreasing expres-
sion of pluripotency genes such as OCT4 and Nanog over time. As 
expected, from day 13 to day 22, the pluripotency gene expres-
sion was almost undetectable. Flow cytometry on iPSC-derived 
AETII cells from both clones showed that SPC-positive cells at 
day 22 were negative for OCT4 (Supplemental Figure 10, A–E for 
C1 and C2 cells).
Since type II cells can spontaneously differentiate into cells 
expressing markers of type I cells (30–32). we assessed the expres-
sion of type I markers T1α, aquaporin-5 (AQ5), and caveolin-1 by 
flow cytometry and qPCR. Flow cytometry revealed that 8%–11% 
of cells expressed type I markers following the differentiation pro-
tocol. Up to 9% of cells were positive for AQ5, 9.6% positive for 
caveolin-1, and 8.1% expressed the type I surface marker T1α in 
clone C1 (Figure 4C).
Differentiation of iPSC-derived AETII to type I cells. To further differen-
tiate iPSC-AETII to AETI, we next examined the effect of modulat-
ing Wnt/β-catenin signaling on type I marker expression in AETII 
cells. We determined whether the selective Wnt/β-catenin inhibitor 
IWR-1 (20, 30) would modulate the differentiation of iPSC-AETII 
cells to AETI cells. Differentiated AETII cells at day 22 were cultured 
on human ECM protein–coated plates in DMEM–10% FBS supple-
mented with 100 mM IWR-1 for 7 days. As data from independent 
experiments indicated, incubation of iPSC-AETII cells with IWR-1 
induced the differentiation of AETII cells to the AETI cell pheno-
type (Figure 4, A–D). Following treatment with IWR-1, there was a 
significant increase in AETI markers AQ5, T1α, and caveolin-1 in 
iPSC-derived AETII compared with untreated AETII, as determined 
by immunostaining (Figure 4, A and B). Flow cytometry revealed 
(as shown in Figure 4C) that up to 92% of cells were positive for 
AQ5, 98% positive for caveolin-1, and 88% of the cells expressed 
the epithelial marker T1α. In contrast, the AETII cell marker SPC 
3G for C1 cells, and Supplemental Figure 5G for C2). Up to 97% of 
cells were positive for SPC, 92% ± 0.9% positive for mucin-1, 89% 
± 0.9% positive for SPB, and the vast majority of the cells, 94% ± 
0.9%, expressed the epithelial surface marker CD54 in clone C1 
and 96.27% ± 0.5% for SPC, 94.42% ± 0.3% for SPB, and 91.54% ± 
1.8% for mucin-1 and 89.83% ± 0.5% for CD54 in clone C2. More-
over, AETII cells were negative for CCSP (a Clara cell marker), p63 
(basal stem cell marker), and SOX2 (proximal airway epithelial cell 
marker) by FACS analysis, indicating that these cells are a relatively 
homogeneous population of type II cells (Figure 3, H and I for C1 
cells, and Supplemental Figure 5, H and I for C2). ELISA measure-
ments of SPC protein in the cell culture supernatants indicated 
that day 13 cells synthesized and secreted SPC at a rate of 16.78 
ng/ml and 15.78 ng/ml in C1 and C2 clones, respectively, every 24 
hours; the rate of secretion was significantly increased on day 22 of 
differentiation when compared with secretion at day 13 (P < 0.05). 
At day 22, the iPSC-AETII cells from C1 and C2 produced 68.5 ng/
ml and 71.5 ng/ml SPC every 24 hours, which was comparable to 
that produced by freshly isolated human AETII cells (82.95 ng/ml) 
(Figure 3J for C1 cells, and Supplemental Figure 5J for C2).
A previous study has found that airway progenitor cells, which 
ultimately give rise to trachea, bronchus and bronchioles, are 
NKX2.1+SOX2+ and sustain high levels of SOX2 expression (15). 
However, by day 22, no NKX2.1+SOX2+ cells or single-positive 
SOX2+ cells were detected in the population of differentiated 
iPSC-AETII cells. All the AETII cells were also negative for CCSP 
and p63 as determined by flow cytometry (Figure 3H for C1 cells, 
and Supplemental Figure 5H for C2 cells). This may indicate that 
these cells are not airway progenitor cells. Since AFE can be theo-
retically differentiated into cells expressing markers of thyroid, 
parathyroid, and lung (1), we checked the expression of CD31 
(endothelial marker), albumin (mature hepatocyte marker), and 
TSGHR (thyroid cell marker) by qRT-PCR to determine whether 
the iPSC-AETII cells were contaminated by cells from these other 
lineages. No specific markers of thyroid, endothelial cells, or hepa-
tocyte lineage were detected in iPSC-AETII cells at day 22, thereby 
confirming the absence of cells from these lineages in the differ-
entiated lung progenitor population (Figure 3I for C1 cells, and 
Supplemental Figure 5I for C2 cells).
The expression of AFE markers (SOX2, PAX9, and TBX1) and DE 
markers (SOX17, CXCR4, and FOXA2) decreased from day 8 to day 
22. By day 32, none of these markers were detectable in iPSC-AETII 
cells. In the case of FOXA2 and SOX2, after activin A removal at day 
6 and switching to NOGGIN/SB-431542, we observed an increase 
in FOXA2 and SOX2 expression at day 8 followed by a decrease in the 
expression of these genes in culture over time (Supplemental Figure 
6, A and C, Supplemental Figure 10B for C1 cells, Supplemental 
Figure 6, B and D, and Supplemental Figure 10C for C2 cells).
Following exposure to alveolar pneumocyte induction medium 
containing Wnt3a, EGF, KGF, and FGF at day 9 of culture, there 
was lower expression of AFE genes, especially SOX2, and there was 
a concomitant upregulation of NKX2.1. After day 8, SOX2 was 
rapidly downregulated while NKX2.1 was upregulated. The expres-
sion of NKX2.1 gradually increased from 24% ± 2% at day 13 to 94% 
± 0.4% at days 20–22 in C1. qRT-PCR and flow cytometry revealed 
that the percentage of SPC-positive cells gradually increased from 
58% ± 1.6% at day 13 to 90% ± 0.4% at days 20–22 during differ-
entiation in the C1 clone. The same pattern of NKX2.1 and SPC 
expression was observed in the C2 clone during differentiation 
from day 8 to day 22 (Supplemental Figure 7, A–D for C1 cells, 
technical advance
 The Journal of Clinical Investigation   http://www.jci.org   Volume 123   Number 11   November 2013 4955
Repopulation of rat and human acellular matrix with iPSC-derived 
AETII. To explore the regenerative potential of iPS-derived AETII 
cells to generate lung tissue in vitro, lungs from adult humans 
and rats were decellularized by processes that remove cellular 
decreased significantly, as determined by flow cytometry (Figure 
4C). qRT-PCR demonstrated a high percentage of expression of type 
I cell markers in iPSC-AETII cells exposed to IWR-1 that was compa-
rable to expression levels of freshly isolated hAETI cells (Figure 4D)
Figure 3
Functional characterization of AETII cells derived from iPSCs, day 22 of differentiation (C1 clone). (A–D) Immunostaining of AETII marker: (A) 
pro-SPC, (B) mucin-1, (C) pro-SPA, (D) pro-SPB. Scale bar: 63 μm. (E and F) Transmission electron microscopy represents (E) human AETII and 
(F) iPSC-derived AETII containing characteristic cytoplasmic laminar bodies. Scale bars: 0.5 μm. (G) qRT-PCR analysis in undifferentiated iPSC, 
DE, AFE, and differentiated AETII cells compared with human AETII from 3 independent experiments. Values from the triplicate PCR reactions 
for a GOI (SPA, SPB, SPC, and mucin-1) were normalized against average GAPDH Ct values from the same cDNA sample. Fold change of GOI 
tra-script levels between iPS-derived AETII and human type II cells equals 2–ΔΔCt, where ΔCt = Ct(GOI) – Ct(GAPDH), and ΔΔCt = ΔCt(AETII) – ΔCt(ATII). 
(H) Flow cytometry analysis for the percentage of positive cells for AETII and AETI markers at day 22. Cells were negative for p63 and SOX2. 
(I) Expression of albumin, CD31, TSHR, and CC10 (CCSP) in iPSC-AETII. Cells were negative for genes indicative of other lineages at day 22. 
(J) Amount of secreted SPC in the iPSC-derived AETII supernatants collected during the time course of differentiation compared with human 
type II cells determined by ELISA. (K) Western blot for pro-SPC in iPSC-AETII at day 22 and β-actin as an internal control. Bars indicate ± SEM 
and n = 3 independent experiments for qRT-PCR, ELISA, and flow cytometry. *P < 0.05.
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fetal lung environment, including vascular perfusion and liquid 
ventilation. In addition to seeding iPSC-AETII cells into decel-
lularized whole rat lung tissue, we also seeded iPSC-AETII cells 
onto slices of either rat or human acellular lung matrix cultured 
in 6-well plates (Figure 1B).
For the rat lung bioreactor experiments, approximately 40 × 106 
cells were injected into the airway through the trachea to repop-
ulate the decellularized rat lung matrix (Figure 1B). The seeded 
matrix was then cultured and maintained for up to 7 days in a 
bioreactor in SAGM (1% FBS). H&E staining showed that iPSC-
AETII cells were able to diffusely repopulate alveolar lung struc-
tures within distal lung. The majority of seeded AETII cells still 
showed approximate AETII morphology — a cuboidal shape and 
round single nuclei (Figure 5, A–C for C1 cells, and Supplemen-
tal Figure 11, A–C for C2 cells). Many AETII cells within the lung 
matrix expressed the type II cell marker, pro-SPC, and NKX2.1. In 
native lung, this marker is normally found on AETII cells. In the 
components but leave behind a scaffold of ECM that retains the 
hierarchical branching structures of airways and vasculature 
(8, 33). This is an assay that was recently developed to test the 
regenerative potential of primary lung epithelial cells or stem 
cell–derived lung epithelial cells (1, 8, 34, 35). Both ATI and 
ATII pneumocytes are differentiated cell types; however, several 
reports have demonstrated that ATII cells retain a level of plas-
ticity. When damage occurs to the ATI pneumocytes, ATII cells 
proliferate and can, in turn, differentiate into ATI cells (29, 30, 
32). Therefore, in this study, we explored the capacity of iPSC-
derived type II cells to repopulate the airway compartment of 
a decellularized lung ECM. We utilized iPSC-AETII cells at day 
28 to repopulate the acellular matrices. This stage seemed most 
suitable because of their commitment to a pneumocyte type II 
phenotype and function. We then cultured the seeded matrix in 
a bioreactor that was designed and described previously (8, 36). 
This bioreactor is capable of replicating key aspects of in vivo 
Figure 4
Functional characterization of AETI cells derived from iPSCs, day 29 of differentiation (C1 clone). (A and B) Immunofluorescent staining of 
alveolar type I marker (A) T1α (B) caveolin-1. Scale bar: 63 μm. (C) Flow cytometry analysis for the percentage of positive cells for alveolar type I 
marker at day 29 in the presence and absence of IWR-1. (y axis, percentage of positive cells). (D) qRT-PCR analysis in AETI cells as compared 
with native human type I (AETI) cells, from 3 independent experiments. Values from the triplicate PCR reactions for a GOI (AQ5, T1α, caveolin-1) 
were normalized against average GAPDH Ct values from the same cDNA sample. Fold change of GOI transcript levels between iPS-derived AETI 
and human type I cells equals 2–ΔΔCt, where ΔCt = Ct(GOI) – Ct(GAPDH) and ΔΔCt = ΔCt(AETI) – ΔCt(hAETI). (y axis, relative gene expression compared 
with human type I cells). Bars indicate ± SEM and n = 3 independent experiments for qRT-PCR, ELISA, and flow cytometry.
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day 7 were stained for proliferating cell nuclear antigen (PCNA) 
expression. The majority of cells on the rat scaffold expressed 
PCNA at both day 3 and day 7 while they displayed few markers 
of apoptotic cell death, as determined by immunostaining for 
caspase-3. However, iPSC-AETII cultured in the rat lung scaf-
fold for 7 days had an increased rate of positive PCNA staining 
reseeded rat lungs, cellular expression of pro-SPC was robust in 
the alveoli by day 3 and remained present at day 7 (Figure 5, D–I 
for C1 cells, and Supplemental Figure 11, D–I for C2 cells).
We investigated whether iPSC-derived AETII are able to pro-
liferate in the acellular matrix. After culturing iPSC-AETII cells 
in the bioreactor, sections from the reseeded lung at day 3 and 
Figure 5
iPSC-derived AETII recellularized 
3D rat lung tissue scaffolds in a bio-
reactor. (A) H&E staining of decel-
lularized rat lung; (B and C) H&E 
staining of 3- and 7-day seeded rat 
lung with iPSC-derived AETII cells 
cultured in a bioreactor. Scale bars: 
25 μm. (D–F) Immunofluorescent 
staining for pro-SPC in AETII seeded 
cells at day 3. (D) DAPI staining; (E) 
pro-SPC; (F) merge (arrows in F indi-
cate cells positive for pro-SPC). (G–I) 
Immunostaining for NKX2.1 at day 
7. (G) DAPI, (H) NKX2.1, (I) merge 
(arrows in 5I indicate cells positive for 
NKX2.1) (J–M) Caspase and PCNA 
immunostaining at day 7 (arrows indi-
cates cells positive for PCNA in L and 
caspase in M). Scale bar: 25 μm. (N) 
Proliferation at day 7 compared with 
day 3. iPSC-AETII displayed a sig-
nificantly increased fractional prolif-
eration (P < 0.05) after 7 days when 
they were stained for PCNA (y axis, 
percentage proliferation based on 
the number of positive nuclei stained 
for PCNA) (O) Immunostaining of 
the few engrafted epithelial cells 
that acquired flattened morphol-
ogy, positive for T1α, and negative for 
NKX2.1 at day 7. Scale bar: 63 μm. 
Arrows in O indicate cells positive for 
T1α. (P) Flow cytometry for SPC, T1α, 
CCSP, p63, and SOX2 before and after 
seeding into rat lung scaffold in bio-
reactor. The number of SPC-positive 
cells decreased during 7-day culture, 
while the number of cells positive for 
T1α increased from 9% to 31.2%. All 
differentiated cells from iPSCs were 
negative for CCSP, p63, and SOX2 
before and after cell seeding.
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such as surfactant protein C (SPC) have been reported, but 
their expression appears to be stochastic, and the cells express-
ing these markers have been difficult to expand (1, 14, 15, 17, 
18, 20). In the present study, we have shown an efficient and 
consistent, step-wise differentiation method to generate DE, 
AFE, and subsequently, a relatively homogeneous population of 
hAETII cells from 2 different iPSC clones (C1, reprogrammed 
from fetal lung fibroblasts; and C2, reprogrammed from neo-
natal fibroblasts). Interestingly, both iPSC clones yield similar 
results and had similar efficiency in differentiating toward DE, 
AFE, AETII and AETI cells, suggesting this protocol can be gen-
eralized to other iPSC lines from other sources. Unlike isolated 
human type II cells, however, these iPSC-AETII cells are capable 
of proliferating for several passages without losing AETII cell–
associated markers, such as SPC, SPA, and mucin-1, and can be 
used to generate tens of millions of cells with which to seed the 
acellular matrix scaffold. The ability to “scale up” a progenitor 
population will be particularly valuable when translating these 
technologies for use in producing human tissues and allows for 
the possibility of using autologous iPSC-derived cells in future 
lung bioengineering work.
Under appropriate culture conditions, iPSC-derived AETII 
cells seeded into either rat decellularized lung bioreactors or 
onto decellularized rat or human lung sections behave similarly 
to isolated human type II cells. In these studies, the iPSC-AETII 
cells were able to diffusely repopulate alveolar lung structures. 
Although the majority of seeded iPSC-AETII cells still showed 
approximate AETII morphology, the percentages of T1α-positive 
cells increased to approximately 30% within the rat lung matrix 
over a 7-day culture period. It is possible that this shift in expres-
sion is a differentiating effect of correct cell-matrix interactions. 
Although type II cells are differentiated cells, these cells nonethe-
less retain a level of plasticity. Following peripheral lung injury, 
type II cells undergo proliferation and differentiation toward 
the type I phenotype. In fact, type II cells are considered to be 
putative alveolar stem cells and are crucial to the natural regen-
erative process of the alveoli (20, 29). The interaction between 
AETII cells and the lung matrix may have had an especially great 
effect, since it is likely that the AETII cells are still in a progeni-
tor state able to give rise to T1α cells when they adhere in regions 
where native lung contains type I cells and maintain a type II cell 
phenotype in regions where type II cells are typically be found. 
Since type I cell markers were not detected in the majority of the 
cells cultured within lung scaffold in bioreactor, it is possible 
that additional stimuli, such as cyclic stretch or exposure to an 
air-liquid interface, may be necessary to promote expression of 
more type I alveolar markers (25, 37, 38).
Future work will concentrate on the production of more types 
of lung progenitors from iPSCs in order to expand the types of 
cells that can be used for lung engineering purposes. In addition, 
longer bioreactor culture time points (e.g., 14 or 21 days) would 
likely allow the epithelial population to further expand within 
the matrix and adopt more characteristic (and functional) pheno-
types. Production of functional epithelium would also be aided by 
exposure to an air-liquid interface or by experiencing the stretch 
produced by breathing with either air or liquid (16). Although our 
results represent only an initial step toward the ultimate goal of 
generating fully functional lungs in vitro, these studies suggest 
that in vitro lung regeneration from autologous cells may be a 
viable strategy for tissue repair and cell therapy applications.
when compared with the day-3 cultures. The data suggest that 
the iPSC-AETII are able to proliferate when they are seeded in 
rat scaffold (Figure 5, J–N for C1 cells, and Supplemental Figure 
11, J–M for C2 cells).
The formation of type I cells in vivo from type II cells is accom-
panied by a loss of the NKX 2.1 protein (1). Consistent with this 
pattern, some engrafted AETII cells acquired a flattened morphol-
ogy and expressed the type 1 pneumocyte marker T1α but lacked 
expression of NKX2.1 protein by costaining (Figure 5O). Moreover 
the number of T1α-positive cells significantly increased from 9.7% 
before cell seeding to 31.2% after culturing cells in the rat lung 
bioreactor. Conversely, the number of SPC-positive cells decreased 
from 98% before cell seeding to 72.3% after 7 days cultured in rat 
lung scaffold in bioreactor. Since type I cells are terminally differ-
entiated cells and are not able to proliferate like type II cells, these 
observations may indicate that the ECM cues support a epithelial 
populations and that iPSC-AETII are able to differentiate to type 
I cells within the lung scaffold (Figure 5P). All of the iPSC-AETII 
cells were negative for CCSP and p63 by FACS analysis after 7 days 
of culture in the rat lung scaffold (Figure 5P).
In parallel experiments, iPSC-derived AETII were cultured on 
sections of rat and human lung matrix. To prepare sections of the 
acellular lung matrix, we treated lungs from adult donors using a 
procedure similar to that previously described (8, 33). Then, iPSC-
AETII cells were seeded onto 600-μm–thick sections of acellular 
human lung matrices and cultured in 6-well plates in SAGM with 
1% FBS for 7 days. The iPSC-AETII cells adhered well to matrix 
surfaces and were initially distributed widely throughout alveoli in 
the matrix in both the rat and human decellularized lung sections. 
Many of the cells still showed AETII morphology, and there was 
robust expression of SPC and NKX2.1 (Figure 6, A–F, on human 
lung sections, and Figure 6, H–K on rat lung sections), while 
some engrafted AETII cells acquired a flattened morphology and 
expressed the AETI marker,\ T1α (Figure 6C on human lung sec-
tions and Figure 6J on rat lung section). iPSC-derived AETII were 
able to proliferate on both rat and human lung sections, as deter-
mined by immunostaining for PCNA and caspase-3 (Figure 6G 
on human lung sections, and Figure 6, L–O on rat lung section).
As a control for these experiments, isolated human type II cells 
from adult human lung (hAETII cells) were also seeded onto decel-
lularized human lung sections. As with the iPSC-AETII cells, many 
of the cells with hAETII morphology expressed SPC and NKX2.1, 
and some of the hAETII cells gave rise to T1α-positive cells (Figure 
6, P–U). Moreover, they were able to replicate on the human scaf-
fold sections, and the majority of cells expressed PCNA, while they 
displayed few markers of apoptotic cell death, as determined by 
immunostaining for caspase-3 (Figure 6V).
Discussion
Lung epithelia remain among the least-studied lineages to be 
derived from ESCs and iPSCs in vitro to date, and few research 
groups have reported on the differentiation toward lung epi-
thelium (5, 14–16). Conditions for directing hESCs or iPSCs to 
differentiate along an alveolar epithelial lineage with homoge-
neity are not yet fully defined, and most protocols generate a 
mixed population of alveolar epithelium from hESCs or iPSCs. 
In the mouse, a NKX2.1:GFP reporter was used to isolate cells 
committed to the lung fate, which were then amenable to fur-
ther differentiation (1). Moreover, in heterogeneous cultures of 
differentiating ESCs, induction of late markers of development 
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Figure 6
iPSC-derived AETII (C1 clone) adhere to sections of acellular rat and human lung matrix. (A–G) iPSC-AETII on human lung sections at 
day 7. (A) H&E. Scale bar: 200 μm (B) Immunostaining for SPC and CCSP. (C) Immunostaining for NKX2.1 and T1α (arrows indicates cells 
positive for SPC in B and T1α in C. Scale bar: 63 μm. (D–F) Immunostaining for NKX2.1. (D), DAPI, (E) NKX2.1, (F) merging. Scale bar: 
50 μm. (G) Caspase and PCNA immunostaining. Scale bar: 49 μm (H–O) iPSC-derived AETII cultured on rat lung sections for 7 days. (H) 
H&E. Scale bar: 200 μm. (I) Immunostaining for SPC and CCSP. (J, K) Immunostaining for NKX2.1 and T1α (arrows indicate cells positive 
for SPC in I, T1α in J, and NKX2.1 in K). Scale bars: 63 μm. (L) DAPI staining, (M) immunostaining for PCNA, and (N) caspase, (O) merge. 
Scale bar: 50 μm. (P–V) Native human AETII cells, isolated from fresh adult human lung, cultured on human lung sections for 7 days. 
(P) H&E. Scale bar: 200 μm. (Q) Immunostaining for SPC and CCSP. Scale bar: 63 μm (R) Immunostaining for NKX2.1 and T1α. Scale 
bar: 63 μm (arrows indicate cells positive for SPC in Q and T1α in R). (S–U) Immunostaining for NKX2.1. (S) DAPI, (T) NKX2.1, (U) merge. 
Scale bar: 50 μm. (V) Caspase and PCNA immunostaining. Scale bar: 49 μm.
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AFE cells were maintained in IMDM differentiation medium with 10% 
FBS, 2 mM l-glutamine, 1 mM nonessential amino acids, 1% antibiotic-
antimycotic, retinoic acid (0.5 μM), FGF-10 (10 ng/ml), EGF (10 ng/ml), 
Wnt3a (100 ng/ml), and KGF (10 ng/ml each) for 10–14 days. Cells were 
maintained in SAGM culture medium (Lonza) plus 1% FBS until seeding 
into lung matrices (1, 14).
Differentiated cells at day 22 were then maintained in DMEM medium 
with 10% FBS, 2 mM l-glutamine, 1 mM nonessential amino acids, 1% 
antibiotic-antimycotic, and 100 mM IWR-1 for 7 days.
Isolation of human type II cells. AETII cells were isolated from human lungs 
rejected for transplant as previously described (31). Briefly, the right mid-
dle lobe was cannulated through the main stem bronchus and removed 
from the rest of the lung. The distal airspaces were lavaged 6–10 times 
using a Ca2+- and Mg2+-free solution (0.5 mm EGTA, 140 mm NaCl, 5 mm 
KCl, 2.5 mm Na2HPO4, 10 mm HEPES, and 6 mm glucose) and lavaged 3 
times with a modified version of this solution (no glucose, 2.0 mm CaCl2, 
and 1.3 mm MgSO4). Elastase (13 units/ml) was instilled into the distal 
airspaces and incubated at 37°C for 30 minutes. Isolated cells were resus-
pended in DMEM and decanted onto PBS- and DMEM-rinsed Petri dishes 
coated with human IgG antibody. After 60 minutes at 37°C, nonadherent 
AETII cells were incubated with a monoclonal antibody against fibroblasts 
(AS02) and pan-mouse IgG Dynabeads for removal by magnet. AETII cells 
were resuspended in DMEM containing 10% FBS, amphotericin B, ceftazi-
dime, tobramycin, and vancomycin.
Flow cytometry and immunochemistry. DE, AFE, and iPSC-AETII cell pop-
ulations were assessed by immunofluorescence or/and flow cytometry 
before differentiation during the induction of DE and AFE and iPSC-
AETII and after cultivation in the decellularized lung matrix.
For immunostaining, cells were washed with PBS, fixed in 4% para-
formaldehyde for 20 minutes at room temperature (RT) and permeabilized 
with 0.1% Triton X-100 in PBS for 15 minutes at RT. Cells were blocked in 
3% BSA in PBS for 60 minutes at RT and incubated with primary antibody 
overnight at 4°C. The next day, cells were washed with PBS and incubated 
with secondary antibody for 2 hours at RT. After washing, the cells were 
incubated with DAPI (1:1000) nuclear stain.
Paraffin sections of cell-seeded lung scaffolds were stained with H&E. 
Additional sections were permeabilized with 0.2% Triton X-100 for 15 
minutes after heat-mediated citric acid antigen retrieval and blocked with 
5% BSA for 1 hour at RT. Primary antibodies were applied overnight at 
4°C. Sections were incubated with secondary antibodies for 1 hour at RT, 
rinsed, treated with DAPI for 1 minute, and mounted with PVA-DABCO 
cover slipping solution. Stained cells and slides were imaged with a Zeiss 
Axiovert 200M inverted microscope and a Hamamatsu camera.
For flow cytometry, cells were dissociated into single-cell suspensions 
by incubation with 0.25% trypsin for 2 minutes and fixed (Fixation/Per-
meabilization Kit, BD Biosciences). After blocking for 30 minutes on ice, 
the cells were incubated with primary antibody in blocking solution for 
30 minutes on ice. The cells were resuspended in 350 μl of Perm/Wash 
buffer after incubation with conjugated secondaries for 30 minutes on ice, 
washed twice, and analyzed by flow cytometry. See Supplemental Table 1 
for antibody information.
Real time qRT-PCR. Total RNA was extracted using the RNeasy Mini Kit 
from QIAGEN, following the manufacturer’s instructions. First-strand 
cDNA was synthesized with random hexamers as primers, using Super-
Script First-Strand Synthesis System according to the manufacturer’s 
protocol (Invitrogen). Each sample was run in triplicate with iQ SYBR 
Green Supermix (Bio-Rad). PCR conditions included an initial denatur-
ation step of 4 minutes at 95°C, followed by 40 cycles of PCR consisting of 
15 seconds at 95°C, 30 seconds at 60°C, and 30 seconds at 72°C. Average 
Ct values from the triplicate PCR reactions for a gene of interest (GOI) 
Methods
Chemical and reagents. Mouse embryonic fibroblasts (MEFs) (GSC-6201) 
were purchased from GlobalStem, Matrigel (354277) was purchased 
from BD, recombinant human WNT3a (5036WN) was purchased from 
R&D. Dispase (07923) was obtained from Stem Cell Technology. Kera-
tinocyte GF (KGF) (PHG0094), FGF-10 (PHG0204), EGF (PHG0311), 
human basic FGF (bFGF) (13256-029), NOGGIN (PHC1506), activin A 
(PHG9014), knockout serum replacement (108280280), and Superscript 
First Strand Synthesis System for RT-PCR (18080-051) were purchased 
from Invitrogen. DMEM: Nutrient Mixture F-12 (DMEM/F-12) (11330-
032), DMEM (11905-092), RPMI 1640 (11875-093), IMDM (12440-053), 
nonessential amino acids (1140-050), l-glutamine (25030164), sodium 
pyruvate (11360-070), 2-mercaptoethanol (21985-023), B27 supplement 
(17504-044), Trypsin (25200-056), penicillin-streptomycin (15140-
122), and FBS were purchased from Life Technology (Gibco). Retinoic 
acid (R2625), gelatin (G1393), SB431542 (S4317), human ECM protein 
(E0282), IWR-1 (I0161), human collagen type I (C7624), and IV (C7521), 
human fibronectin (F0895), human ECM protein (E0282), CHAPs 
(C3023), benzonase (E1014), sodium deoxycholate (D6750), elastase 
(E8140), and Triton X-100 (T9284), were purchased from Sigma–Aldrich. 
Sodium nitroprusside dihydrate (71778) was obtained from Fluka. 
DNase I (LS006333) was purchased from Worthington Biochemical 
Corp. Small Airway Growth Medium (SAGM) (CC-3119) and ampho-
tericin B (17836R) were purchased from Lonza. The human SPC ELISA 
kit (E01S0168) was obtained from Life Science Advanced Technologies 
Inc. Peracetic acid (PAA) (P05020) was obtained from Pfalz & Bauer. FBS 
(SH30071.03) was obtained from Hyclone. iQ SYBR Green Supermix 
(170-8882) was obtained from Bio-Rad. All antibodies were used in this 
study are listed in Supplemental Table 1.
Cultivation of human iPSCs. The human iPSC lines, iPSC (IMR90, C1) and 
iPSC (neonatal foreskin, C2), utilized here were provided by James A. Thom-
son (Department of Anatomy, University of Wisconsin–Madison, Madison, 
Wisconsin, USA) (11). Both human iPSC lines were generated by lentiviral 
transduction of isolated human skin fibroblasts (IMR90, C1 clone) and 
neonatal foreskin fibroblast (C2 clone) with OCT-4, SOX2, Nanog, and lin28 
genes. These induced pluripotent human stem cells have been extensively 
characterized; they have normal karyotypes and telomerase activity, express 
cell-surface markers and genes that characterize human ESCs, and maintain 
the developmental potential to differentiate into advanced derivatives of 
all 3 primary germ layers (11). Both lines were cultured and maintained as 
described previously (11). Briefly, iPSCs were propagated on irradiated MEF 
feeder layers in DMEM-F12 medium supplemented with 20% knockout 
serum replacement, 4 ng/ml bFGF, 1 mM glutamine, 1% mM nonessential 
amino acids, and 0.1 mM β-mercaptoethanol at 37°C, 5% CO2, and 90%–
95% humidity, with medium changes every day. Undifferentiated iPSCs 
were passaged every 4–5 days onto fresh feeders by mechanical dissociation 
using a Stem Cell Cutting Tool (VWR).
In vitro differentiation of iPSCs into AETII cells. iPSCs were differentiated 
into alveolar epithelium in a directed differentiation protocol via DE and 
AFE. iPSCs were differentiated into DE under conditions described previ-
ously (39, 40). Briefly, hiPSCs were cultured in RPMI 1640 medium supple-
mented with 100 ng/ml activin A, 2 mM l-glutamine, and 1% antibiotic-
antimycotic for 48 hours; 1×B27 supplement, 0.5 mM sodium butyrate, 
and 0.1% FBS were added into the same medium, and the cells were cul-
tured for another 4 days, with daily medium changes (41).
DE generated by exposure to activin A were trypsinized, reseeded at a 
ratio of 1:1–2 on human ECM protein–coated plates, and differentiated 
into AFE with IMDM + 5% FBS, 2 mM l-glutamine, 1 mM nonessential 
amino acids, 1% antibiotic-antimycotic supplemented with 200 ng/ml 
NOGGIN, and 10 mM SB-431542 for 2 days (1, 14).
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transferred onto decellularized human lungs slices in SAGM–1% FBS and 
cultured for 1 week; medium was changed every other day.
ELISA for SPC. ELISA was performed on cell culture medium collected 
during iPSC-AETII differentiation to quantify secreted SPC (Life Science 
Advanced Technology) according to the manufacturer’s instructions. SPC 
values were normalized to the total number of cells.
Western blotting. Cells were incubated in RIPA buffer supplemented with 
protease inhibitors (Complete Mini; Roche,) on ice for 30 minutes. Pro-
tein concentration was determined from cell lysates using a bicinchoninic 
acid protein assay (Thermo Fisher Scientific). Cell lysates were denatured, 
and equal amounts of protein per sample were subjected to SDS-PAGE 
and immunoblotting as described previously (8). HRP-conjugated goat 
anti-mouse and goat anti-rabbit secondaries were detected by enhanced 
chemiluminescence.
Proliferation assay. To assess cell proliferation within the lung scaffold, 
lungs seeded and cultured with AETII for 3 days and 7 days were fixed 
in 4% PBS-buffered paraformaldehyde (pH 7.4) and postfixed with 70% 
EtOH. The immunocytochemical staining against human caspase and 
PCNA was performed as described in the immunostaining section. The 
images were visualized with a Zeiss Axiovert 200M inverted microscope 
and imaged with a Hamamatsu camera. The percentage of positive nuclear 
staining was calculated based on total cell numbers in 3 high-power fields.
Statistics. Statistics were done with Origin (OriginLab). The data were 
expressed as mean ± SEM (all error bars represent ± SEM). Unpaired, 
2-tailed Student’s t tests were performed to evaluate whether the 2 groups 
were significantly different from each other. P values of less than 0.05 
(2-tailed) were considered statistically significant.
Study approval. All animal experiments were performed with the approval 
of the IACUC of Yale University. All studies using human lung tissue were 
approved by the University of Michigan and the University of North Caro-
lina institutional review boards.
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were normalized against average GAPDH Ct values from the same cDNA 
sample. Fold change of GOI transcript levels between sample A and sam-
ple B = 2–ΔΔCt, where ΔCt = Ct(GOI) – Ct(GAPDH) and ΔΔCt = ΔCt(A) – ΔCt(B). 
See Supplemental Table 2 for primers.
Transmission electron micrographs. Cell samples were prepared following a 
modified protocol from Schmiedl et al. (42). Briefly, native human AETII 
and iPSC-AETII cells were fixed at 37°C with a 2.5% glutaraldehyde/2.0% 
paraformaldehyde mixture in 0.2 M sodium cacodylate for 30 minutes, fol-
lowed by 2 hour incubation at 4°C. The samples were dehydrated following 
a standard ethanol series. The samples were postprocessed by OsO4 fixation 
and en block uranyl acetate staining. Then 70- to 80-nm sections were taken 
and incubated in uranyl acetate and lead citrate for increased contrast. 
Images were taken using a Philips Tecnai transmission electron microscope.
Preparation of decellularized ECM scaffolds. Three-month-old Fischer 
or Sprague-Dawley rats were anesthetized with sodium pentobarbital 
according to the guidelines set forth by the American Veterinary Medi-
cal Association (60 mg/kg i.p.). Lung ECM scaffolds were prepared as 
previously described (8, 43). Lungs were perfused with heparin (50 U/ml, 
Sigma-Aldrich) in PBS and removed with the heart and trachea. The pul-
monary artery and trachea were cannulated, and the lungs were perfused 
through the pulmonary artery with sodium nitroprusside (1 ml/ml; Fluka) 
before being treated with decellularization solution (8 mM CHAPS, 1M 
NaCl, 5 mM EDTA in PBS) for 2–3 hours at 37°C. Scaffolds were treated 
with benzonase endonuclease (90 U/ml; Sigma-Aldrich) for 1 hour at 37°C, 
followed by extensive rinsing with PBS, antibiotics, and antimycotics.
Human lungs were obtained from beating-heart donors or warm 
autopsy as arranged through Gift of Life Michigan, and were decellular-
ized as we have recently described (33). Lung samples were agitated in ster-
ile deionized, distilled water and incubated in 0.1% Triton X-100 for cell 
lysis. Samples were washed with sterile PBS, incubated with 2% sodium 
deoxycholate, and washed again. Lungs were incubated in 1 M NaCl to lyse 
residual nuclei. After decanting NaCl, tissues were rinsed and incubated 
with 30 μg/ml DNAse in 1.3 mM MgSO4 and 2 mM CaCl2. The DNAse 
solution was decanted, and tissues were washed with sterile PBS (33).
Culture of cells on rat lung ECM scaffolds. Rat scaffolds were mounted in the 
bioreactor as described previously (8). Cannulas were connected to tubing 
loops to provide perfusion and introduction of cells to the scaffold. Forty 
million iPSC-AETII cells were suspended in 3–5 ml of culture medium 
(SAGM–1% FBS) and introduced into the airway compartment; perfusion 
was initiated at 1 ml/min immediately after cell seeding. In additional 
experiments, 6 × 106 native human AETII cells — isolated from human lung 
— were introduced into the upper right lobe of a decellularized rat lung. The 
full volume of culture medium was changed once at day 3 or 4, and samples 
were harvested at days 1, 3, and 7 and saved for histology. In parallel experi-
ments, iPSC-AETII cells were seeded onto sections of decellularized rat lung 
at a concentration of 1.5 × 105 cells/slice in SAGM–1% FBS medium for 7 
days. Finally, 3 × 105 of either AETII cells or native human AETII cells were 
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